Cellusion, a Japanese regenerative medicine startup, and Minaris Regenerative Medicine, a global CDMO, announced Letter of Intent (LOI) for the manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative therapy in the U.S.
The companies will develop the manufacturing process of Cellusion’s leading program, CLS001, a novel regenerative medicine product for bullous keratopathy treatment. Minaris’ Allendale, NJ team will perform process optimization to meet FDA requirements.
